Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for crohn's disease before and after delivery

Journal of Clinical Gastroenterology

Volumn 43, Issue 7, 2009, Pages 613-616

  Kane, Sunanda ^a   Ford, Joyce ^b   Cohen, Russell ^c   Wagner, Carrie ^b  

^a MAYO CLINIC   (United States)

^b CENTOCOR INC   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Breast milk; Crohn's disease; Infliximab; Nursing; Pregnancy

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; PARACETAMOL;

ADULT; APGAR SCORE; ARTICLE; BIRTH; BIRTH WEIGHT; BREAST FEEDING; BREAST MILK; CESAREAN SECTION; CLINICAL ARTICLE; COLON; CROHN DISEASE; DELIVERY; DRUG BLOOD LEVEL; DRUG MILK LEVEL; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; ILEUM; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; RELAPSE; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; VAGINAL DELIVERY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; MILK, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67650992265     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31817f9367     Document Type: Article

References (25)

1. Mogadam M, Korelitz BI, Ahmed SW, et al. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol. 1981;75:265-269.
2. Mottet C, Juillerat P, Gonvers JJ, et al. Pregnancy and Crohn's disease. Digestion. 2005;71:54-61.
3. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol. 1984;6:211-216.
4. Bortoli A, Saibeni S, Tatarella M, et al; The Study Group for Inflammatory Bowel Diseases GSMII. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol. 2007;22: 542-549.
5. Fonager K, Sorensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426-2430.
6. Norgard B, Pedersen L, Christensen LA, et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007; 102:1406-1413. (Pubitemid 46976292)
7. American Academy of Pediatrics, Policy statement. Breastfeeding and the use of human milk. Pediatrics. 2005;115: 496-506.
8. Larsen LA, Ito S, Koren G. Prediction of milk/plasma concentration ratio of drugs. Ann Pharmacother. 2003;37: 1299-1306.
9. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005;100:102-105.
10. Van de Perre P. Transfer of antibody via mother's milk. Vaccine. 2003;21:3374-3376.
11. Hanson LA. Breastfeeding provides passive and likely long-lasting active immunity. Ann Allergy Asthma Immunol. 1998; 81:523.
12. McLean B, Holmes IH. Transfer of antirotaviral antibodies from mothers to their infants. J Clin Microbiol. 1980; 12: 320-325.
13. Askanase AD, Miranda-Carus ME, Tang X, et al. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum. 2002;46:269-271.
14. Targan SR, Hanauer SB, van Deventer SJ, et al., for the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337: 1029-1035.
15. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N EnglJ Med. 1999;340:1398-1405. (Pubitemid 29205403)
16. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastro-enterology. 1999;117:761-769.
17. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
18. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99: 2385-2392.
19. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-738.
20. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4: 1255-1258.
21. Peltier M, James D, Ford J, et al. Infliximab levels in breast-milk of a nursing Crohn's patient [Abstract]. Am J Gastroenterol. 2001;96:P258.
22. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
23. Saji F, Samejima Y, Kamiura S, et al. Dynamics of immuno-globulins at the feto-maternal interface. Rev Reprod. 1999;4: 81-89.
24. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365-3369.
25. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459.